Bayer/Onyx’s Nexavar Proves Hard To Topple In Liver Cancer

A study of sorafenib in combination with Astellas/Genentech’s Tarceva showed that in hepatocellular carcinoma, two targeted therapies are not better than sorafenib alone. These results, coupled with the failure of Bristol-Myers Squibb’s brivanib to demonstrate non-inferiority, reaffirm Nexavar’s place in first-line treatment and have analysts looking ahead to new indications.